Autologous stem cell transplantation in multiple myeloma: Improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients

Bone Marrow Transplantation

Volumn 31, Issue 3, 2003, Pages 163-170

  Terpos, E ^a   Apperley, J F ^a   Samson, D ^a   Giles, C ^a   Crawley, C ^a   Kanfer, E ^a   Olavarria, E ^a   Goldman, J M ^a   Rahemtulla, A ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Age; Autologous transplantation; Melphalan; Multiple myeloma; Nonsecretory multiple myeloma; Total body irradiation

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 MICROGLOBULIN; CARMUSTINE; CD34 ANTIGEN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; METHYLPREDNISOLONE; PENICILLIN G; VINCRISTINE;

ADULT; AGED; AGING; ARTICLE; AUTOGRAFT; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CELL INFILTRATION; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE COURSE; FEBRILE NEUTROPENIA; FEMALE; HEALTH STATUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; OUTCOMES RESEARCH; PERIPHERAL BLOOD STEM CELL; PLASMA CELL; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURGICAL MORTALITY; SURVIVAL TIME; TREATMENT OUTCOME; WHOLE BODY RADIATION;

AGE FACTORS; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 0037294795     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703818     Document Type: Article

References (42)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36.
2. Boccadoro M, Marmont F, Tribalto M et al. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 1992; 10: 334-342.
3. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6663 patients from 27 randomised trials. J Clin Oncol 1998; 16: 3832-3842.
4. UK Myeloma Forum. British Committee for Standards in Haematology. Diagnosis and management of multiple myeloma. Br J Haematol 2001; 115: 522-540.
5. Cohen HJ, Bartolucci A. Age and the treatment of multiple myeloma. Southeastern Cancer Study Group experience. Am J Med 1985; 79: 316-324.
6. Clavio M, Casciaro S, Gatti AM et al. Multiple myeloma in the elderly: clinical features and response to treatment in 113 patients. Haematologica 1996; 81: 238-244.
7. Riccardi A, Mora O, Brugnatelli S et al. Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospective randomised protocol. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer 1998; 77: 485-491.
8. Pileri A, Palumbo A, Boccadoro M. Current therapeutic options for multiple myeloma. Haematologica 1996; 81: 291-294.
9. Quaglino D, Di Leonardo G, Pasqualoni E et al. Therapeutic management of hematological malignancies in elderly patients. Biological and clinical considerations. Part IV: multiple myeloma and Waldenstrom's macroglobulinemia. Aging (Milano) 1998; 10: 5-12.
10. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
11. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
12. Palumbo A, Triolo S, Argentino C et al. Dose-intensive melphalan with stem cell support (MEL 100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248-1253.
13. Lenhoff S, Hjorth M, Holmberg E et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 7-11.
14. Harousseau JL, Attal M, Divine M et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma. Blood 1995; 85: 3077-3085.
15. Siegel DS, Desikan KR, Mehta J et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51-54.
16. Badros A, Barlogie B, Siegel E et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600-607.
17. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cells transplants for multiple myeloma: identification of favourable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
18. Gupta D, Bybee A, Cooke F et al. CD34 + -selected peripheral blood progenitor cell transplantation in patients with multiple myeloma: tumour cell contamination and outcome. Br J Haematol 1999; 104: 166-177.
19. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. Br J Haematol 1998; 102: 1115-1123.
20. Tribalto M, Amadori S, Cudillo L et al. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study. Haematologica 2000; 85: 52-58.
21. Dimopoulos MA, Hester J, Huh Y et al. Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma. Br J Haematol 1994; 87: 730-734.
22. Bensinger WI, Rowley SD, Demirer T et al. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol 1996; 14: 1447-1456.
23. Bjorkstrand BB, Ljungman P, Svensson H et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711-4718.
24. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intregroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731-735.
25. Barlogie B, Jagannath S, Naucke S et al. Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone Marrow Transplant 1998; 21: 1101-1107.
26. Majolino I, Vignetti M, Meloni G et al. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Haematologica 1999; 84: 844-852.
27. Bjorkstrand B. European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma. Semin Hematol 2001; 38: 219-225.
28. Attal M, Payen C, Facom T et al. Single versus double transplant in myeloma: a randomised trial of the 'Intergroupe Francais du Myelome'. Bone Marrow Transplant 1998; 21(Suppl. 1): S206 (abstract).
29. Alegre A, Diaz-Mediavilla J, San-Miguel J et al. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM and PETHEMA. Bone Marrow Transplant 1998; 21: 133-140.
30. Alexanian R, Dimopoulos MA, Hester J et al. Early myeloablative therapy for multiple myeloma. Blood 1994; 84: 4278-4282.
31. Vesole DH, Jagannath S, Tricot G et al. Autologous bone marrow and peripheral blood stem cell transplantation in multiple myeloma. Cancer Invest 1996; 14: 378-391.
32. Vesole DH, Crowley JJ, Catchatourian R et al. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. J Clin Oncol 1999; 17: 2173-2179.
33. Tricot G, Spencer T, Sawyer J et al. Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol 2002; 116: 211-217.
34. Rajkumar SV, Fonseca R, Dispenzieri A et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 2000; 26: 979-983.
35. Harousseau JL, Attal M, Divine M et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood 1995; 85: 3077-3085.
36. Sirohi B, Powles R, Treleaven J et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000; 25: 533-539.
37. Lahuerta JJ, Martinez-Lopez J, Grande C et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish registry for transplantation in multiple myeloma. Br J Haematol 2000; 109: 138-147.
38. Desikan KR, Tricot D, Dhodapkar M et al. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MELCY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplant 2000; 25: 483-487.
39. Blade J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukaemia. Hematol Oncol Clin North Am 1999; 13: 1259-1272.
40. Smith DB, Harris M, Gowland et al. Non-secretory multiple myeloma: a report of 13 cases with a review of the literature. Hematol Oncol 1986; 4: 307-313.
41. Sirohi B, Powles R, Kulkarni S et al. Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: The need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplant 2001; 28: 29-37.
42. Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131-3136.